1. Background {#sec1}
=============

Chronic stress dysregulates the hypothalamic-pituitary-adrenal axis, elevating the production of stress related hormones, epinephrine, and norepinephrine \[[@B1]\]. These catecholamines seem to enhance the expression of vascular endothelial growth factor (VEGF) and the matrix of metalloproteinases (MMPs) in malignant tumors, contributing to tumor progression \[[@B2]\]. It is known that *β*2-AR is a member of a large family of G-protein-coupled receptors and is responsible for transduction signals from catecholamine ligands \[[@B3], [@B4]\]. Once *β*2-AR binds to catecholamine ligands, it stimulates a G-protein receptor, resulting in adenylyl cyclase activity and, subsequently, in the generation of intracellular cyclic AMP (cAMP) that activates protein kinase A (PKA), which modulates several cellular functions \[[@B5]\]. A growing number of scientific evidences have verified that *β*2-AR is expressed by malignant neoplastic cells and that, under chronic psychological stress, through catecholamine induced activation, it could regulate a wide spectrum of tumor cell mechanisms including proliferation, apoptosis, angiogenesis, migration, and metastases \[[@B1], [@B2], [@B6]--[@B25]\].

Particularly, investigations in oral cancer cell lines have demonstrated that *β*2-AR signaling upregulates interleukin-6 (IL-6) mRNA, a cytokine that is involved in angiogenesis and tumor progression process, increasing proliferation and invasion of the tumor \[[@B16], [@B18]\]. Furthermore, Shang et al. also reported that positive *β*2-AR immunoexpression in oral cancer is significantly correlated with age, tumor size, clinical stage, and cervical lymph node metastasis in OSCC patients, suggesting a role of *β*2-AR in the metastasis of oral cancer \[[@B16]\]. In contrast, our group, in a retrospective clinical study, showed that patients with OSCC, who exhibited strong *β*2-AR expression by malignant epithelial cells, presented higher survival rates compared with weak/negative *β*2-AR expression \[[@B21]\].

Although *β*2-AR is present in normal oral tissues, the exact differences between *β*2-AR expression levels in normal oral epithelium and oral cancer are not so clear \[[@B3], [@B16], [@B18], [@B21]\]; for example, *β*2-AR was highly expressed in OSCC tissue when compared to adjacent normal oral mucosa \[[@B16]\]. In turn, Bernabé et al. showed no significant differences between *β*2-AR mRNA levels in normal oral mucosa and OSCC specimens \[[@B18]\].

In order to contribute with recent studies and investigate the role of *β*2-AR in OSCC, the present study aimed to analyze the expression of *β*2-AR in the tumor-free surgical margin and at the invasive front of a large sample of OSCC to verify if *β*2-AR expression is correlated with tumor-free surgical margins and the invasive front of OSCCs and to explore associations between *β*2-AR expression levels and clinicopathological features.

2. Patients and Methods {#sec2}
=======================

2.1. Patients and Tumor Samples {#sec2.1}
-------------------------------

The present retrospective study was based on the analysis of 62 patients previously studied by Bravo-Calderón et al. \[[@B21]\]. All patients were submitted to surgical treatment for primary oral squamous cell carcinoma at the Head and Neck Surgery and Otorhinolaryngology Department of the A.C. Camargo Cancer Center, São Paulo, Brazil, from 1970 to 2000. The inclusion criteria were (i) primary OSCC located in the oral tongue, floor of the mouth, retromolar area or inferior gingiva confirmed by biopsy; (ii) patients submitted to surgery as the initial treatment followed or not by radiotherapy; (iii) clinical stages II, III, and IV; and (iv) tumor and morphologically normal/nondysplastic tumor-free surgical margin tissues available for microscopic analysis. Patients with other simultaneous primary tumors, or with distant metastases at the time of admission, undergoing preoperative chemotherapy and/or radiotherapy were not included. Clinical data of the patients were collected from the hospital records and included age, gender, ethnic group, tobacco and alcohol consumption, tumor location, and disease stage according to the TNM system of the International Union Against Cancer (UICC) \[[@B26]\], and treatment (surgery, postoperative adjuvant radiotherapy) and clinical follow-up (recurrence, cervical lymph node metastasis, distant metastasis, or occurrence of second primary tumor). The present study was approved by the Research Ethics Committee of the A.C. Camargo Cancer Center, São Paulo, Brazil (\#1385/10).

A formalin-fixed 3** ** *μ*m thick section of tumor tissue was selected and paraffin-embedded for hematoxylin and eosin staining and immunohistochemistry analysis of *β*2-AR. Three observers (Denise Tostes Oliveira, Gustavo Amaral Lauand, Diego Mauricio Bravo-Calderón) analyzed the tumor sections without knowledge of the clinical data. Histopathological malignancy grade of OSCC was determined according to the Bryne et al. system \[[@B27]\]. Tumor infiltration to adjacent structures, vascular embolization, and lymph node metastases (pN+) were also reported.

2.2. Beta-2 Adrenergic Receptor Expression in the Tumor-Free Surgical Margin of Oral Squamous Cell Carcinoma {#sec2.2}
------------------------------------------------------------------------------------------------------------

Sections of the 62 OSCC specimens were deparaffinized in xylene and hydrated using graded alcohol/water baths. Antigen retrieval was performed using 10** **mM citrate buffer (pH 6.0) in a domestic pressure cooker (Nigro, model Eterna 4.5 L, Araraquara, SP, Brazil) for 4** **min, and then the endogenous peroxidase activity was blocked by incubation in 3% H~2~O~2~ for 30** **min. Tumor sections were incubated for 18 hours at 4°C in a humid chamber with the anti-beta-2 adrenergic receptor primary antibody (Santa Cruz Biotechnology, sc-9042, Santa Cruz, CA, USA) and diluted 1 : 50 in phosphate buffered saline (PBS) with bovine serum albumin solution (Sigma, A9647, St. Louis, MO, USA) to block nonspecific reactions. Next, the tumor sections were sequentially incubated with Post Primary Block (Novocastra, NovoLink Max Polymer, RE7260-K, Newcastle Upon Tyne, UK) for 30** **min, followed by incubation with the Polymer from the same kit. The antigen-antibody reactions were revealed using 3.3′ diaminobenzidine tetrahydrochloride (DAB/Sigma, D-5637, St. Louis, MO, USA) for 5** **min in the dark. Tumor sections were counterstained with Harris hematoxylin before being dehydrated and prepared with a cover slip. The vascular smooth muscle within the sections served as the positive internal control. For a negative control, the primary antibody was omitted during the immunohistochemical staining. All the OSCC specimens were immunostained in a single session.

Ten microscopic fields of the tumor-free margins were captured using 400x magnification to analyze the immunohistochemical expression of *β*2-AR. Images were obtained digitally with a camera (Axiocam MRc, ZEISS, Jena, Germany) attached to a light microscope (Axioskop 2 Plus, ZEISS, Jena, Germany) and saved in a computer program system (Axiovision 4.6, ZEISS, Jena, Germany). The immunohistochemical expression of *β*2-AR was evaluated as previously described \[[@B21]\]. Briefly, the ImageJ software (Java-based image processing and analysis program of public-domain developed by Wayne Rasband NIH, Bethesda, MD, USA) was used to segment the representative tumor images. Variations in the brown intensity of the malignant cells positive for *β*2-AR expression were categorized according to the following RGB channel value ranges: R (red) channel was from 90 to 194; G (green) channel was from 50 to 140; B (blue) channel was from 45 to 147; the R value should be greater than the B value; the G value should be greater than the B value.

Ten images captured from the surgical margins of each OSCC were automatically segmented using the MATLAB computing language-based software according to the criteria listed above. This software measures, based on the number of pixels, each segmented area (determining the *β*2-AR immunopositive regions). After performing this computer-assisted immunohistochemistry analysis, the average of the *β*2-AR expression levels in ten surgical margin images was calculated. Next, the averages of 62 OSCC specimens, previously obtained by Bravo-Calderón et al. \[[@B21]\], were placed in ascending order and the median was established as the cut-off point to classify the specimens as exhibiting weak/negative (averages 0.62 to 23.86) or strong (averages 25.99 to 79.63) *β*2-AR expression. This measurement of *β*2-AR expression by epithelial cells of surgical margins was then subjectively confirmed by three investigators (Denise Tostes Oliveira, Gustavo Amaral Lauand, and Diego Mauricio Bravo-Calderón) without knowledge of the histopathological features and patient clinical status. In case of discordance between these analyzers, the criterion of the subjective evaluation was retained because this assessment involved the entire specimen.

In addition, knowing that most antigens are influenced adversely by formalin fixation \[[@B28]\], a confirmation of *β*2-AR expression pattern was conducted through immunohistochemical staining of 19 additional frozen sections of OSCC obtained from the Anatomical Pathology Service, Clinical Hospital University of Santiago, Santiago de Compostela, Spain.

2.3. Statistical Analysis {#sec2.3}
-------------------------

All statistical analysis was performed using the SPSS 13.0 for windows software (SPSS Inc., Chicago, IL, USA). Correlation between *β*2-AR expressions in the tumor-free surgical margins and at the invasive front of OSCCs was verified by Pearson\'s correlation coefficient test. The association between the *β*2-AR expression and clinicopathological variables was analyzed by the chi-square or Fisher\'s exact tests. For all tests, *p* ≤ 0.05 was considered to represent a statistically significant result.

3. Results {#sec3}
==========

Immunohistochemical analysis of the 62 OSCC specimens revealed a positive expression of *β*2-AR in parakeratinized stratified squamous epithelium of all tumor-free surgical margins, and 50 (80.6%) demonstrated strong expression of *β*2-AR levels. *β*2-AR immunostaining was detected at the cytoplasm and at the plasma membrane of normal epithelial cells in tumor-free surgical margins. Similarly, the same pattern of *β*2-AR expression (cytoplasmic and membranous) was identified in malignant epithelial cells at the invasive front of tumors.

Interestingly, Pearson\'s correlation coefficient test detected a statistically significant and positive correlation between the *β*2-AR expression levels in tumor-free surgical margins and at the invasive front of tumors (*r* = 0.383; *p* = 0.002) ([Figure 1](#fig1){ref-type="fig"}). Effectively, most (64.5%) of the 62 OSCC specimens had an increase of *β*2-AR expression levels in the tumor-free surgical margins, and it was accompanied by an increase of the expression levels at the invasive front. In other words, those specimens with weak *β*2-AR expression in the tumor-free surgical margin also exhibited weak/negative immunostaining of this protein in their respective invasive tumor front; and similarly, when the immunoexpression of *β*2-AR was strong in normal oral epithelial cells, at the tumor-free surgical margin, the expression levels of this protein in malignant epithelial cells at the invasive front of the tumor were also high ([Figure 1](#fig1){ref-type="fig"}).

On the other hand, 22 (35.5%) OSCC samples presented no correlation between *β*2-AR levels in the tumor-free margins and at the invasive front of tumors, as shown in [Figure 1](#fig1){ref-type="fig"}. In 20 of these noncorrelated cases (32.25% of the total sample), the invasive front of tumor presented a decrease of *β*2-AR expression levels when compared to their respective tumor-free surgical margins ([Figure 1](#fig1){ref-type="fig"}). On the other hand, the pattern of *β*2-AR expression found in the tumor-free surgical margin and at the invasive tumor front of OSCC is illustrated in [Figure 2](#fig2){ref-type="fig"}.

An additional analysis was performed to confirm our findings in formalin-fixed, paraffin-embedded tissue material by the evaluation of 19 new OSCC frozen specimens. *β*2-AR expression, in this sample, was verified in most OSCC specimens, being positively immunoexpressed in 87.5% of the tumor-free surgical margins and in 55.5% of the front of invasion. In the basal and corneum layers of the surgical margins or in the keratin pearls of oral cancers, no immunoexpression of *β*2-AR was detected. Furthermore, the cytoplasmic and membranous expressions of *β*2-AR were confirmed in oral epithelial cells adjacent to the tumor, as well as in the malignant epithelial cells of OSCC.

3.1. Associations between *β*2-AR Expression and Clinicopathological Variables {#sec3.1}
------------------------------------------------------------------------------

To determine the possible clinical significance of *β*2-AR expression in oral cancer and the associations between this protein expression and the clinicopathological features of OSCC patients, chi-square or Fischer\'s exact tests were performed.

No statistically significant associations were found regarding immunohistochemical expression of *β*2-AR in the tumor-free surgical margins and clinical variables evaluated ([Table 1](#tab1){ref-type="table"}). On the other hand, *β*2-AR immunoexpression at the invasive tumor front was statistically associated with alcohol consumption (*p* = 0.038), simultaneous consumption of alcohol, and tobacco (*p* = 0.010) and with the clinical T stage (*p* = 0.014), as shown in [Table 1](#tab1){ref-type="table"}. Most OSCC patients with weak/negative expression of *β*2-AR at the invasive front of tumor exhibited alcohol consumption or alcohol and tobacco consumption. In addition, strong *β*2-AR expression by malignant epithelial cells was more frequently detected in patients with early clinical stage of T1/T2.

Regardless of the area that was considered for analysis, either the tumor-free surgical margin or the invasive tumor front, no statistically significant association between *β*2-AR expression and the histopathological characteristics was shown, including grade of malignancy, lymph nodes involvement (pN+), vascular embolization and perineural invasion, and muscular or bone infiltration ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

Although several studies have described the functional localization of *β*2-AR in a wide variety of cells including those of the tumor microenvironment, the expression pattern of this receptor in normal oral epithelium and in malignant epithelial cells is not well defined yet \[[@B1]--[@B3], [@B6], [@B8]--[@B24]\]. Our immunohistochemical analysis of a large cohort of OSCC specimens has shown a cytomembranous expression of *β*2-AR in normal oral epithelial cells of all tumor-free surgical margins, except for the corneum and basal layers ([Figure 2](#fig2){ref-type="fig"}). These findings corroborate previous reports that identified *β*2-AR as the main adrenergic receptor subtype in cultured human oral keratinocytes and those in which a RT-PCR assay verified the expression of *β*2-AR mRNA in 14 of 15 specimens of normal oral mucosa \[[@B3], [@B18]\]. Collectively, data obtained by us and by mentioned reports \[[@B3], [@B18]\] suggest that *β*2-AR is constitutively expressed in normal oral epithelium.

Concerning OSCC, similarly to normal epithelium, the invasive front of tumor is considered as the most progressed region by Piffkò et al. \[[@B29]\], and approximately three to six tumor cell layers or detached tumor cell groups were positively immunostained for *β*2-AR at the cytoplasm and plasma membranes of malignant epithelial cells, except for the keratin pearls that were negative ([Figure 2](#fig2){ref-type="fig"}). In addition, the present study is the first to demonstrate that the expression of *β*2-AR in surgical margins is positively correlated with the invasive front of tumor expression levels (*r* = 0.383; *p* = 0.002) ([Figure 1](#fig1){ref-type="fig"}). Despite methodological differences, our findings corroborate the observations proposed by Bernabé et al. \[[@B18]\] which reported no expressive difference in *β*2-AR mRNA expression in not matched specimens of normal mucosa and OSCC \[[@B18]\]. Contradictorily, Shang et al. \[[@B16]\] reported that *β*2-AR immunoexpression is higher in OSCC tissue than in the adjacent normal oral mucosa. However, comparing with our present results, it is impracticable because the aforementioned analysis was carried out in a small number of surgical margins. Besides, evaluations through correlation tests were not performed by Shang et al. \[[@B16]\], and according to the authors, their findings of *β*2-AR immunostaining in surgical margins might be caused by the diversity of experiments \[[@B16]\]. Moreover, the accuracy of our findings determined in formalin-fixed, paraffin-embedded tissues was validated positively by the analysis of the OSCC frozen specimens.

Biological evidence has demonstrated that chronic psychological stress through catecholamine-induced activation of *β*2-AR can influence the progression of a wide variety of malignant tumors \[[@B1], [@B2], [@B6]--[@B25]\]. However, the effects of stress related hormones can be stimulatory or inhibitory, depending on the type of hormone and the tumor type \[[@B25]\]. In this context, the role of *β*2-AR in the progression of oral cancer is not well established. Thus, the scientific literature has demonstrated that *β*2-AR immunoexpression by malignant cells is significantly correlated with age, tumor size, clinical stage, and cervical lymph node metastasis in OSCC patients \[[@B16]\]. Nevertheless, the present clinical study revealed that patients clinically classified as T3 or T4 exhibited a higher frequency of weak/negative *β*2-AR expression at the invasive tumor front ([Table 1](#tab1){ref-type="table"}). In addition, considering that *β*2-AR was presented in all tumor-free surgical margins, it was expected that no statistically significant associations would be found regarding immunohistochemical expression in the normal oral epithelial cells and clinicopathological variables evaluated (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

On the other hand, the evidence that, in certain OSCCs, *β*2-AR expression by tumoral cells may decrease ([Figure 1](#fig1){ref-type="fig"}), as previously shown in patients with oral cancer and weak/negative *β*2-AR expression and low survival rates, compared with strong *β*2-AR expression \[[@B21]\], reinforces previous findings obtained by Yu et al. \[[@B10]\]. Yu et al. demonstrated that genetic silencing of *β*2-AR increases cell migration and invasion in normal prostate cells and that weak expression of this protein was associated with metastases and worst survival rates in prostate cancer patients. Considering the present results, other studies with *β*2-AR expression should be performed to further elucidate the role of this receptor. In vitro analyses are suggested with the stimulatory and inhibitory factors for *β*2-AR.

5. Conclusions {#sec5}
==============

Thereby, in light of these results we can conclude that although the present study reinforces that *β*2-AR is constitutive in normal oral epithelial cells and is positively correlated with the expression levels of *β*2-AR by OSCC cells, further clinical, cellular, and animal studies are needed to elucidate the role of *β*2-AR in oral cancer, specially, in relation to the importance of its decrease on tumor progression.
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![Correlation of the averages of *β*2-AR immunoexpression in OSCC specimens. The lines correspond to the cut-off point that classifies the invasive tumor fronts (green line) and the surgical margins (blue line) as exhibiting weak/negative (averages 0.62 to 23.86) or moderate/strong (averages 25.99 to 79.63) *β*2-AR expression.](JO2016-3531274.001){#fig1}

![Expression pattern of *β*2-AR in OSCC specimens. (a and b) OSCC with strong expression of *β*2-AR in both surgical margin and invasive front of tumor. (c and d) OSCC with weak expression of *β*2-AR in both surgical margin and invasive front of tumor. (e and f) OSCC with reduced expression of *β*2-AR at the invasive front of the tumor when compared to surgical margin. Note the membranous and/or cytoplasmic expression pattern of *β*2-AR in immunostained cells (a, b, c, d, e, and f: immunohistochemistry *β*2-AR, original magnification ×400).](JO2016-3531274.002){#fig2}

###### 

Association between clinical parameters and *β*2-AR expression in 62 patients with oral squamous cell carcinoma.

  Variable                            Beta-2 adrenergic receptor                                                   
  ----------------------- ----------- ---------------------------- ----------- ----------- ----------- ----------- ----------------
  Gender                  Male        8 (66.7)                     44 (88)     0.091       31 (86.1)   21 (80.8)   0.729
  Female                  4 (33.3)    6 (12)                       5 (13.9)    5 (19.2)                            
                                                                                                                   
  Ethnic group            White       10 (83.3)                    45 (90)     0.612       33 (91.7)   22 (84.6)   0.439
  Not white               2 (16.7)    5 (10)                       3 (8.3)     4 (15.4)                            
                                                                                                                   
  Age                     ≤58 years   8 (66.7)                     25 (50)     0.299       22 (61.1)   11 (42.3)   0.143
  \>58 years              4 (33.3)    25 (50)                      14 (38.9)   15 (57.7)                           
                                                                                                                   
  Tobacco^\#^             Yes         11 (100)                     42 (93.3)   0.999       31 (100)    22 (88)     0.083
  No                      0 (0)       3 (6.7)                      0 (0)       3 (12)                              
                                                                                                                   
  Alcohol^\#^             Yes         10 (90.9)                    32 (69.6)   0.256       27 (84.4)   15 (60)     **0.038^*∗*^**
  No                      1 (9.1)     14 (30.4)                    5 (15.6)    10 (40)                             
                                                                                                                   
  Tobacco + alcohol^\#^   Yes         10 (90.9)                    29 (64.4)   0.144       26 (83.9)   13 (52)     **0.010^*∗*^**
  No                      1 (9.1)     16 (35.6)                    5 (16.1)    12 (48)                             
                                                                                                                   
  T stage                 T1/T2       6 (50)                       28 (56)     0.708       15 (41.7)   19 (73.1)   **0.014^*∗*^**
  T3/T4                   6 (50)      22 (44)                      21 (58.3)   7 (26.9)                            
                                                                                                                   
  N stage                 N+          6 (50)                       24 (48)     0.901       18 (50)     12 (46.2)   0.765
  N0                      6 (50)      26 (52)                      18 (50)     14 (53.8)                           
                                                                                                                   
  Clinical stage          II          3 (25)                       16 (32)     0.74        9 (25)      10 (38.5)   0.257
  III/IV                  9 (75)      34 (68)                      27 (75)     16 (61.5)                           
                                                                                                                   
  Recurrence^\#\#^        Yes         6 (50)                       20 (40)     0.528       17 (47.2)   9 (34.6)    0.321
  No                      6 (50)      30 (60)                      19 (52.8)   17 (65.4)                           
                                                                                                                   
  Metastases              Yes         0 (0)                        1 (2)       0.999       0 (0)       1 (3.8)     0.419
  No                      12 (100)    49 (98)                      36 (100)    25 (96.2)                           
                                                                                                                   
  Second primary tumor    Yes         1 (8.3)                      8 (16)      0.675       5 (13.9)    4 (15.4)    0.999
  No                      11 (91.7)   42 (84)                      31 (86.1)   22 (84.6)                           

*N*: number of cases; *p*: *p* value obtained by chi-square test or Fisher\'s exact test; ^\#^excluding patients with lost records; ^\#\#^local and/or regional recurrence; ^*∗*^statistically significant result.

###### 

Association between histopathological parameters and *β*2-AR expression in 62 patients with oral squamous cell carcinoma.

                                        Beta-2 adrenergic receptor                                                   
  ------------------------- ----------- ---------------------------- ----------- ----------- ----------- ----------- -------
  Malignancy grading        M. diff.    10 (83.3)                    44 (88)     0.645       31 (86.1)   23 (88.5)   0.999
  L. diff.                  2 (16.7)    6 (12)                       5 (13.9)    3 (11.5)                            
                                                                                                                     
  Vascular embolization     Yes         9 (75)                       26 (52)     0.149       23 (63.9)   12 (46.2)   0.165
  No                        3 (25)      24 (48)                      13 (36.1)   14 (53.8)                           
                                                                                                                     
  Perineural infiltration   Yes         9 (75)                       36 (72)     0.999       24 (66.7)   21 (80.8)   0.219
  No                        3 (25)      14 (28)                      12 (33.3)   5 (19.2)                            
                                                                                                                     
  Muscular infiltration     Yes         11 (91.7)                    43 (86)     0.999       31 (86.1)   23 (88.5)   0.999
  No                        1 (8.3)     7 (14)                       5 (13.9)    3 (11.5)                            
                                                                                                                     
  Bone infiltration^\#^     Yes         1 (8.3)                      5 (10.2)    0.999       5 (14.3)    1 (3.8)     0.227
  No                        11 (91.7)   44 (89.8)                    30 (85.7)   25 (96.2)                           
                                                                                                                     
  Lymph node involvement    *p*N+       4 (33.3)                     26 (52)     0.245       18 (50)     12 (46.2)   0.765
  *p*N0                     8 (66.7)    24 (48)                      18 (50)     14 (53.8)                           

*N*: number of cases; *p*: *p* value obtained by chi-square test or Fisher\'s exact test; M. diff.: more differentiated tumor; L. diff.: less differentiated tumor; ^\#^excluding patients with lost records.
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